Suppr超能文献

世界卫生组织内分泌肿瘤分类第5版中甲状腺肿瘤诊断的变化。

Changes in the diagnosis of thyroid tumours in the 5th edition of the WHO classification of endocrine neoplasms.

作者信息

J Dušková

出版信息

Cesk Patol. 2024;60(1):59-63.

Abstract

The WHO classification of thyroid tumours enters its second half-century of development with the 5th edition. Compared to the previous 4th edition of the clas- sification, the permanent increase in information is mainly at the molecular biological level. This has changed the view of very traditional entities - the preferred name for polynodous goiter is (given the monoclonal nature of some nodules) follicular nodular thyroid disease. Some terminological relics have also been re- moved - Hürthle cells are definitively referred to as oncocytes. Follicular adenoma has a new subtype with papillary arrangement (and missing nuclear features of papillary carcinoma). In the already used NIFTP unit, subtypes smaller than 10 mm and oncocytic are newly defined. All oncocytic tumours have an arbitrarily set minimum proportion of oncocytes at 75 %. A multidisciplinary approach to the treatment of thyropathies and the stratification of therapeutic procedures according to risk brought about the introduction of grading into several nosological units of papillary, follicular, and medullary carcinomas. Grading using the number of mitoses determines their quantification at 2 mm² instead of the previously used non-uniform HPFs (high power fields of view). Clarification was made on the basis of genetic findings in a number of other, less frequent diagnoses (e.g. classification of squamous cell carcinoma among anaplastic). Among rare tumors a new category of salivary gland - type carcinomas is formulated with two representatives: mucoepidermoid and secretory carcinoma. Cribriform morular carcinoma previously classified as a variant of papillary carcinoma is newly separated on the basis of the immunological and genetic profile into the newly created category of tumors of uncertain histogenesis. This category also includes sclerosing mucoepidermoid carcinoma with eosinophilia. Microcarcino- ma as a separate entity is not included in the 5th edition. A tumor smaller than 10 mm must be characterized by the appropriate features of the corresponding category. Thyroblastoma replaces terminologically malignant teratoma from the previous classification. Part of the newly established diagnostic criteria is also applicable in FNAB diagnosis. The newly introduced grading in some nosological units can exceptionally change the diagnosis (NIFTP/EFVPTC/non-invasive HG FVPTC), but above all it will affect the choice of therapeutic procedures.

摘要

世界卫生组织甲状腺肿瘤分类随着第5版进入了其发展的第二个半个世纪。与之前的第4版分类相比,信息的持续增加主要在分子生物学层面。这改变了对一些非常传统实体的看法——鉴于某些结节的单克隆性质,多结节性甲状腺肿的首选名称是滤泡结节性甲状腺疾病。一些术语遗迹也已被去除——许特莱细胞被明确称为嗜酸性细胞。滤泡性腺瘤有一种新的具有乳头结构的亚型(且缺乏乳头状癌的核特征)。在已使用的NIFTP单元中,新定义了小于10毫米的亚型和嗜酸性亚型。所有嗜酸性肿瘤都任意设定嗜酸性细胞的最小比例为75%。甲状腺疾病治疗的多学科方法以及根据风险对治疗程序进行分层导致在乳头状癌、滤泡状癌和髓样癌的几个病种单元中引入了分级。使用有丝分裂数进行分级确定其定量为2平方毫米,而不是先前使用的不均匀的高倍视野(HPF)。基于一些其他不太常见诊断的基因发现进行了澄清(例如间变性癌中鳞状细胞癌的分类)。在罕见肿瘤中,制定了一类新的唾液腺型癌,有两个代表:黏液表皮样癌和分泌性癌。先前归类为乳头状癌变体的筛状桑葚状癌基于免疫和基因特征被重新划分为新创建的组织发生不确定肿瘤类别。该类别还包括伴有嗜酸性粒细胞增多的硬化性黏液表皮样癌。微小癌作为一个单独实体未被纳入第5版。小于10毫米的肿瘤必须具有相应类别的适当特征。甲状腺母细胞瘤在术语上取代了先前分类中的恶性畸胎瘤。新建立的部分诊断标准也适用于细针穿刺抽吸活检(FNAB)诊断。一些病种单元中新引入的分级可能会异常改变诊断(NIFTP/EFVPTC/非侵袭性高分级FVPTC),但最重要的是它将影响治疗程序的选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验